SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it is nearing completion of the “first-in-man” study of a medical device to treat Human Immunodeficiency Virus (HIV), the disease that causes Acquired Immune Deficiency Syndrome (AIDS). In the study, an HIV-infected individual recently initiated treatment with the Aethlon Hemopurifier® as part of a 30-day case study being conducted at the Jattinder Gambhir Hospital (J.G. Hospital) in Punjab, India. The study protocol, which calls for the administration of up to twelve Hemopurifier® treatments, is scheduled to be completed on January 23rd. The study goal is to demonstrate that the Hemopurifier® can safely and effectively reduce viral load and trigger replenishment of CD4 immune cells in the absence of drug therapy.
